title: In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
abstract: CGS 16949A inhibited the conversion of [4-14C]androstenedione (A) to [4-14C]estrone by human placental microsomes in a competitive manner (Ki = 1.6 nM). Aminoglutethimide, also a competitive inhibitor, had a Ki = 0.7 microM in this assay system. The Km for the aromatization of A was 0.11 microM. Using ovarian microsomes from immature rats primed with pregnant mare's serum gonadotrophin and using [4-14C]testosterone conversion to [4-14C]estradiol as a measure of aromatase activity, the Km was 42 nM. At a substrate concentration 3-fold the Km, CGS 16949A was 180 times more potent as an inhibitor than aminoglutethimide, exhibiting half-maximal inhibition at 1.7 nM as compared to 0.3 microM. In vivo CGS 16949A lowered ovarian estrogen synthesis by gonadotropin-primed, androstenedione treated, immature rats by 90% at a dose of 260 micrograms/kg (PO). A dose of 100 mg/kg of aminoglutethimide was needed to produce this same effect. CGS 16949A at a dose of 4 mg/kg (PO) induced uterine atrophy (aromatase inhibition) without inducing adrenal hypertrophy - indicating a lack of inhibition of corticosterone secretion, while aminoglutethimide at 40 mg/kg (PO) induced adrenal hypertrophy without inducing uterine atrophy. CGS 16949A was neither androgenic nor estrogenic in rats using standard bioassays. The data suggest that CGS 16949A may serve as a potent and selective agent for modulating estrogen-dependent functions.
authors.affiliation: Research Department, CIBA-GEIGY Corporation, Summit, NJ 07901.
authors.forename: R E
authors.initials: RE
authors.lastname: Steele
authors.forename: L B
authors.initials: LB
authors.lastname: Mellor
authors.forename: W K
authors.initials: WK
authors.lastname: Sawyer
authors.forename: J M
authors.initials: JM
authors.lastname: Wasvary
authors.forename: L J
authors.initials: LJ
authors.lastname: Browne
mesh_terms: D000728:Androgens / Q000378:metabolism; D000818:Animals; D047072:Aromatase Inhibitors; D003345:Corticosterone / Q000378:metabolism; D004965:Estrogen Antagonists / Q000494:pharmacology*; D017316:Fadrozole; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008861:Microsomes / Q000378:metabolism; D009570:Nitriles / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000201:enzymology; D010920:Placenta / Q000201:enzymology / Q000378:metabolism; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000728:Androgens; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D007093:Imidazoles; D009570:Nitriles; D017316:Fadrozole; D003345:Corticosterone